Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis

Journal of Hepatology

Volumn 64, Issue 2, 2016, Pages 399-408

  Armstrong, Matthew J ^a   Hull, Diana ^a   Guo, Kathy ^a   Barton, Darren ^a   Hazlehurst, Jonathan M ^a   Gathercole, Laura L ^a   Nasiri, Maryam ^a   Yu, Jinglei ^a   Gough, Stephen C ^b   Newsome, Philip N ^a   Tomlinson, Jeremy W ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adipose tissue; Glucagon like peptide 1; Insulin sensitivity; Lipolysis; Non alcoholic fatty liver

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; HEMOGLOBIN A1C; INSULIN; LEPTIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; STABLE ISOTOPE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN;

ADIPOSE TISSUE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG MECHANISM; FATTY ACID BLOOD LEVEL; GLUCONEOGENESIS; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; IN VITRO STUDY; IN VIVO STUDY; INSULIN SENSITIVITY; LIPID LIVER LEVEL; LIPOGENESIS; LIPOLYSIS; LIPOTOXICITY; LIVER; LIVER BIOPSY; LIVER CELL; LOW DRUG DOSE; MICRODIALYSIS; MUSCLE TISSUE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS FAT; TISSUE SPECIFICITY; ANALOGS AND DERIVATIVES; DRUG EFFECTS; DRUG MONITORING; FEMALE; GLUCOSE CLAMP TECHNIQUE; INSULIN RESISTANCE; LIPID METABOLISM; MALE; METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

ADULT; AGED; BODY MASS INDEX; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE CLAMP TECHNIQUE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPID METABOLISM; LIRAGLUTIDE; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; TREATMENT OUTCOME;

EID: 84954384684     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.08.038     Document Type: Article

References (40)

1. M.J. Armstrong, L.A. Adams, A. Canbay, and et al. Extra-hepatic complications of nonalcoholic fatty liver disease Hepatology 59 2014 1174 1197
2. A.J. Sanyal, E.M. Brunt, D.E. Kleiner, and et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis Hepatology 54 2011 344 353
3. G. Marchesini, M. Brizi, G. Bianchi, and et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome Diabetes 50 2001 1844 1850
4. R. Lomonaco, C. Ortiz-Lopez, B. Orsak, and et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease Hepatology 55 2012 1389 1397
5. G. Musso, M. Cassader, F. De Michieli, and et al. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism Hepatology 56 2012 933 942
6. K.L. Donnelly, C.I. Smith, S.J. Schwarzenberg, and et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease J Clin Invest 115 2005 1343 1351
7. J.E. Lambert, M.A. Ramos-Roman, J.D. Browning, and et al. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease Gastroenterology 146 2014 726 735
8. K. Cusi Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications Gastroenterology 142 2012 e6
9. M.J. Armstrong, D.D. Houlihan, I.A. Rowe, and et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program Aliment Pharmacol Ther 37 2013 234 242
10. S. Ben-Shlomo, I. Zvibel, M. Shnell, and et al. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase J Hepatol 54 2011 1214 1223
11. S. Sharma, J.E. Mells, P.P. Fu, and et al. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy PLoS One 6 2011 e25269
12. J. Shirakawa, H. Fujii, K. Ohnuma, and et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice Diabetes 60 2011 1246 1257
13. J.E. Mells, P.P. Fu, S. Sharma, and et al. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet Am J Physiol Gastrointest Liver Physiol 302 2012 G225 G235
14. X. Ding, N.K. Saxena, S. Lin, and et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice Hepatology 43 2006 173 181
15. J. Lee, S.-W. Hong, S.W. Chae, and et al. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice PLoS One 7 2012 e31394
16. J.L. Trevaskis, P.S. Griffin, C. Wittmer, and et al. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice Am J Physiol Gastrointest Liver Physiol 302 2012 G762 G772
17. Y.-S. Lee, S. Shin, T. Shigihara, and et al. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis Diabetes 56 2007 1671 1679
18. L. Zhang, M. Yang, H. Ren, and et al. GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK Liver Int 33 2013 794 804
19. D.A. D'Alessio, S.E. Kahn, C.R. Leusner, and et al. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal J Clin Invest 93 1994 2263 2266
20. M. Zander, S. Madsbad, J.L. Madsen, and et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study Lancet 359 2002 824 830
21. R.L. Prigeon, S. Quddusi, B. Paty, and et al. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect Am J Physiol Endocrinol Metab 285 2003 E701 E707
22. L. Orskov, J.J. Holst, J. Møller, and et al. GLP-1 does not acutely affect insulin sensitivity in healthy man Diabetologia 39 1996 1227 1232
23. M.J. Armstrong, D. Barton, P. Gaunt, and et al. Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial BMJ Open 3 2013 e003995
24. M.J. Armstrong, J.M. Hazlehurst, and D. Hull Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis Diabetes Obes Metab 16 2014 651 660
25. J.M. Hazlehurst, L.L. Gathercole, M. Nasiri, and et al. Glucocorticoids fail to cause insulin resistance in human subcutaneous adipose tissue in vivo J Clin Endocrinol Metab 98 2013 1631 1640
26. L.L. Gathercole, S.A. Morgan, I.J. Bujalska, and et al. Regulation of lipogenesis by glucocorticoids and insulin in human adipose tissue PLoS One 6 2011 e26223
27. M. Seghieri, E. Rebelos, A. Gastaldelli, and et al. Direct effect of GLP-1 infusion on endogenous glucose production in humans Diabetologia 56 2013 156 161
28. M. Gutniak, C. Orskov, J.J. Holst, and et al. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus N Engl J Med 326 1992 1316 1322
29. M. Toft-Nielson, S. Madsbad, and J.J. Holst The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones Diabetes 45 1996 552 556
30. B.R. Gedulin, S.E. Nikoulina, P.A. Smith, and et al. Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight Endocrinology 146 2005 2069 2076
31. G. Svegliati-Baroni, S. Saccomanno, C. Rychlicki, and et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis Liver Int 31 2011 1285 1297
32. J.E. Campbell, and D.J. Drucker Pharmacology, physiology, and mechanisms of incretin hormone action Cell Metab 17 2013 819 837
33. G. Boden Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver Curr Diab Rep 6 2006 177 181
34. H. Gao, X. Wang, Z. Zhang, and et al. GLP-1 amplifies insulin signaling by up-regulation of IRbeta, IRS-1 and Glut4 in 3T3-L1 adipocytes Endocrine 32 2007 90 95
35. J. Vendrell, R. El Bekay, B. Peral, and et al. Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance Endocrinology 152 2011 4072 4079
36. A. Perea, C. Viñambres, F. Clemente, and et al. GLP-1 (7-36) amide: effects on glucose transport and metabolism in rat adipose tissue Horm Metab Res 29 1997 417 421
37. M.L. Villanueva-Peñacarrillo, L. Márquez, N. González, and et al. Effect of GLP-1 on lipid metabolism in human adipocytes Horm Metab Res 33 2001 73 77
38. A. Gastaldelli, S.A. Harrison, R. Belfort-Aguilar, and et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis Hepatology 50 2009 1087 1093
39. E. Bertin, P. Arner, J. Bolinder, and et al. Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo J Clin Endocrinol Metab 86 2001 1229 1234
40. A. Gastaldelli, S. Harrison, R. Belfort-Aguiar, and et al. Pioglitazone in the treatment of NASH: the role of adiponectin Aliment Pharmacol Ther 32 2010 769 775